All In Biotech

Drug Trial Radar · NCT07002177

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

An Open-label, Multicenter, Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of Multiple Combination Therapies With FWD1802 in Subjects With ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer

Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

196

Planned (sponsor's estimate)

Start

Jun 1, 2025

Primary completion

May 1, 2028

Study completion Nov 1, 2028

Sponsor

Sponsor type
Industry
First posted
Jun 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer

Conditions

  • Metastatic Breast Cancer
  • Breast Cancer Stage I
  • Breast Cancer Stage II
  • Locally Advanced Breast Cancer (LABC)
  • ER+ Breast Cancer

Interventions

  • FWD1802Drug

    orally QD with 28 days each cycle, treatment till disease progression or intolerable toxicity or withdraw for other reasons

  • Palbociclib 125mgDrug

    Dose: 125 mg Route: Orally Frequency: Once daily (QD) Schedule: Administered for 21 consecutive days, followed by a 7-day treatment break (3-weeks-on/1-week-off), constituting a 28-day cycle

  • Ribociclib 200Mg Oral TabletDrug

    Dose: 600 mg Route: Orally Frequency: Once daily (QD) Schedule: Administered for 21 consecutive days, followed by a 7-day treatment break, constituting a 28-day cycle

  • Abemaciclib 150 MGDrug

    Dose: 150 mg Route: Orally Frequency: BID Schedule: Everyday

  • Everolimus 10 mgDrug

    Dose: 10 mg Route: Orally Frequency: QD Schedule: Everyday

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase Ib- Dose-Limiting Toxicity (DLT).Time frame: Approximately 1.5 years
  2. Phase Ib- Maximum Tolerated Dose (MTD).Time frame: Approximately 1.5 years
  3. Phase Ib- Recommended Phase II Dose (RP2D).Time frame: Approximately 1.5 years
  4. Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Approximately 2 years
  5. Severity Grading of Adverse EventsTime frame: Approximately 2 years
  6. Clinically Significant Abnormalities in 12-Lead ECG ParametersTime frame: Approximately 2 years
  7. Vital Sign AbnormalitiesTime frame: Approximately 2 years
  8. Serious Adverse Events (SAEs) IncidenceTime frame: Approximately 2 years
  9. Phase II- Investigator-assessed Objective Response Rate (ORR) based on RECIST v1.1.Time frame: Approximately 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center, Shanghai

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.